


Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Original) A medicament for the prevention and/or treatment of cancers which comprises as an active ingredient a substance selected from the group consisting of a compound represented by the following general formula (I) and a pharmacologically acceptable salt thereof, and a hydrate thereof and a solvate thereof:



wherein A represents hydrogen atom or acetyl group,
E represents a 2,5-di-substituted or a 3,5-di-substituted phenyl group, or a monocyclic or a fused polycyclic heteroaryl group which may be substituted, provided that the compound wherein said heteroaryl group is (1) a fused polycyclic heteroaryl group wherein the ring which binds directly to - CONH - group in the formula (I) is a benzene ring, (2) unsubstituted thiazol-2-yl group, or (3) unsubstituted benzothiazol-2-yl group is excluded,

ring Z represents an arene which may have one or more substituents in addition to the group represented by formula - O - A wherein A has the same meaning as that defined above and the group represented by formula - CONH - E wherein E has the same meaning as that defined above, or a heteroarene which may have one or more substituents in addition to the group represented by formula - O - A wherein A has the same meaning as that defined above and the group represented by formula - CONH - E wherein E has the same meaning as that defined above.

2. (Original) The medicament according to claim 1, wherein A is a hydrogen atom.

3. (Currently Amended) The medicament according to claim 1 ~~any one of claims 1 or 2~~, wherein ring Z is a C₆ to C₁₀ arene which may have one or more substituents in addition to the group represented by formula - O - A wherein A has the same meaning as that defined in the general formula (I) and the group represented by formula - CONH - E wherein E has the same meaning as that defined in the general formula (I), or a 5 to 10-membered heteroarene which may have one or more substituents in addition to the group represented by formula - O - A wherein A has the same meaning as that defined in the general formula (I) and the group represented by formula - CONH - E wherein E has the same meaning as that defined in the general formula (I).

4. (Original) The medicament according to claim 3, wherein ring Z is a benzene ring which may have one or more substituents in addition to the group represented by formula - O - A wherein A has the same meaning as that defined in the general formula (I) and the group represented by formula - CONH - E wherein E has the same meaning as that defined in the general formula (I), or a naphthalene ring which may have one or more substituents in addition to the group represented by formula - O - A wherein A has the same meaning as that defined in the general formula (I) and the group represented by formula - CONH - E wherein E has the same meaning as that defined in the general formula (I).

5. (Original) The medicament according to claim 4, wherein ring Z is a benzene ring which is substituted with halogen atom(s) in addition to the group represented by formula - O - A wherein A has the same meaning as that defined in the general formula (I) and the group represented by formula - CONH - E wherein E has the same meaning as that defined in the general formula (I).

6. (Original) The medicament according to claim 4, wherein ring Z is a naphthalene ring.

7. (Currently Amended) The medicament according to claim 1 any one of claims 1 to 6, wherein E is a 2,5-di-substituted phenyl group or a 3,5-di-substituted phenyl group.

8. (Original) The medicament according to claim 7, wherein E is a 2,5-di-substituted phenyl group wherein at least one of the said substituents is trifluoromethyl group, or a 3,5-di-substituted phenyl group wherein at least one of the said substituents is trifluoromethyl group.

9. (Original) The medicament according to claim 8, wherein E is 3,5-bis(trifluoromethyl)phenyl group.

10. (Currently Amended) The medicament according to claim 1 any one of claims 1 to 6, wherein E is a monocyclic or a fused polycyclic heteroaryl group which may be substituted, provided that the compound wherein said heteroaryl group is (1) a fused polycyclic heteroaryl group wherein the ring which binds directly to - CONH - group in the formula (I) is a benzene ring, (2) unsubstituted thiazol-2-yl group, or (3) unsubstituted benzothiazol-2-yl group is excluded.

11. (Original) The medicament according to claim 10, wherein E is a 5-membered monocyclic heteroaryl group which may be substituted, provided that the compounds wherein said heteroaryl group is unsubstituted thiazol-2-yl group are excluded.